Journal article icon

Journal article

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt

Abstract:

Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during transfection tyrosine kinases, is a potent radiosensitiser in xenograft models. We compared WBRT with WBRT plus vandetanib in the treatment of patients with melanoma brain metastases.In this double-blind, multi-cen...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1038/bjc.2016.318

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More from this funder
Name:
Oxford Experimental Cancer Medicine Centre
Funding agency for:
Middleton, M
More from this funder
Name:
National Institute for Health Research Oxford Biomedical Research Centre
Funding agency for:
Middleton, M
Publisher:
Cancer Research UK
Journal:
British Journal of Cancer More from this journal
Volume:
115
Issue:
10
Pages:
1193–1200
Publication date:
2016-10-06
Acceptance date:
2016-09-13
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Pmid:
27711083
Language:
English
Keywords:
Pubs id:
pubs:648326
UUID:
uuid:fe02d5dc-b6eb-4c95-a309-1883b9109cf3
Local pid:
pubs:648326
Source identifiers:
648326
Deposit date:
2016-10-14

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP